We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

CarGurus (NASDAQ:CARG – Free Report) had its price target raised by Needham & Company LLC from $39.00 to $45.00 in a research note released on Thursday morning, Marketbeat.com reports. The firm ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Stock futures edged higher on Friday morning, following an eventful week marked by strong bank earnings and a slew of mixed economic data. Here are some of Frid ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

The acquisition's total consideration is $200 million in cash and Symbotic will pay Walmartup to $350 million in additional contingent consideration in future periods dependent upon the quantity of ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...